Goodsurance

Drug prices & Part D

Federal Court Rules Drug Companies Cannot Override 340B Discount Rules Without Government Approval

A unanimous three-judge panel told major pharmaceutical manufacturers that only the federal government can decide how hospitals and clinics receive their mandated drug discounts.

By the Goodsurance editorial teamJuly 22, 2026

The U.S. Court of Appeals for the District of Columbia Circuit ruled on July 21, 2026, that drug manufacturers may not unilaterally replace the traditional upfront-discount structure of the 340B Drug Pricing Program with a post-purchase rebate model. The case was brought by four drug companies, Novartis, Johnson and Johnson Health Care Systems, Bristol Myers Squibb, and Eli Lilly, each arguing it had the legal right to redesign how eligible hospitals and clinics receive their 340B savings.

The three-judge panel disagreed. Writing for the court, Judge Bradley Garcia found that while the statute permits both upfront discounts and rebates, control over which approach is used belongs to the HHS Secretary, not manufacturers. "The statute places the Secretary, not the manufacturers, in the driver's seat," Garcia wrote. The ruling affirms a 2025 district court decision and does not prevent HHS from approving a rebate model in the future.

The 340B program requires drug companies to sell medications at steep discounts to hospitals, community health centers, and other covered entities that serve large numbers of low-income or uninsured patients, many of whom are also Medicare beneficiaries. The savings help those facilities fund services across their patient populations.

Drug companies cannot rewrite 340B discount rules on their own. A federal appeals court put that authority firmly with the government.

In plain words

A federal appeals court said four large drug companies cannot change the rules of a drug-discount program on their own. The program is called 340B. It lets certain hospitals and clinics buy medicines at a lower price. The companies wanted to switch from giving discounts upfront to paying rebates later. The court said only the government can make that call. Many hospitals in this program treat Medicare patients, and the savings help fund their care.

Source: American Hospital Association
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

OIG Report Finds Medicare Part B Drug Price-Substitution Mechanism Saved 1.6 Million Dollars in 2024

An annual OIG analysis posted Wednesday found CMS applied price reductions to 14 physician-administered drugs based on 2024 market data, while reporting that errors in manufacturer price submissions blocked the review of 31 additional drugs.

September 24, 2026

Drug prices & Part D

CMS Must Send Final Written Price Offers to 15 Drug Makers by September 30 in Third Negotiation Cycle

The final statutory step before drug manufacturers accept or reject Medicare prices arrives this week. CMS must issue written maximum fair price offers by September 30, and manufacturers have until October 31 to respond. Agreed prices would take effect in 2028.

September 23, 2026

Drug prices & Part D

About 140,000 Wellcare Part D Members Were Dropped Mid-Year After Small New Premiums Were Added to Their Previously Free Plans

KFF Health News found that Wellcare terminated tens of thousands of drug plan members in April 2026 when minimal monthly premiums went unpaid, leaving many without prescription coverage and at risk for permanent Medicare drug enrollment penalties.

September 21, 2026

Drug prices & Part D

MedPAC September Meeting Finds IRA Changes Improved Drug Affordability for Enrollees but May Be Accelerating Overall Medicare Part D Spending

Medicare's congressional advisory commission opened its new study cycle in September finding that Inflation Reduction Act drug benefit changes have helped individual beneficiaries while putting upward pressure on total program spending and future premiums.

September 20, 2026

Drug prices & Part D

Medicare's 2027 Part D Base Beneficiary Premium Will Be 41 Dollars and 33 Cents, Hitting the Inflation Reduction Act's Annual Cap

CMS set the 2027 Part D base beneficiary premium at 41 dollars and 33 cents in July, representing a 6 percent rise from the prior year and the maximum the IRA allows, a benchmark that shapes what drug plans charge as open enrollment approaches.

September 19, 2026

Drug prices & Part D

Federal Watchdog Adds Medicare Part D GLP-1 Overdispensing to Its Active Study List

The Office of Inspector General announced a new evaluation of GLP-1 prescribing patterns in Part D, as the Medicare obesity drug bridge program continues to attract enrollment.

September 17, 2026